Unique Adverse Events With Newly Approved Drug Reviewed By Melanoma Expert

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D., and Katharina C. Kahler, M.D., have published an article in the Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab. Both drugs are anti-CTLA-antibodies with similar mechanisms of action but manufactured by different companies. Ipilimumab is an immunoglobulin G1 with a plasma half-life of 12 to 14 days... via Health News from Medical News Today Read More Here..

For a Free Step By Step Guide for Dating Dos and Don'ts check http://end2endwebs.com

Lake forest health and fitness http://healthandfitness1blog.blogspot.com/2012/08/unique-adverse-events-with-newly.html